Biomarker and shear stress in secondary pediatric pulmonary hypertension

Pektas, Ayhan; Olguntürk, Fatma Rana; Kula, Serdar; Cilsal, Erman; Aydın, Oğuz; Tunaoğlu, F. Sedef

doi:10.3906/sag-1609-13

Cited by 7 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionsupporting

confidence: 87%

“…Compared to patients with normal invasive pulmonary arterial pressure, patients with PH had higher serum CA 125 levels, which was consistent with the results seen in chronic obstructive pulmonary disease (16) and congenital heart disease (17). WHO-FC, 6MWD, NT-proBNP, pericardial effusion, mRAP, CI, and S v O 2 are well-established prognostic markers of IPAH (18).…”

Section: Ca 125 Is Weakly Associated With Established Markers Of Ph Severitysupporting

confidence: 83%

“…Rahimi-Rad et al reported that patients with PH had higher serum CA 125 levels than those without PH in chronic obstructive pulmonary disease ( 16 ). A similar phenomenon was also observed in congenital heart disease ( 17 ). Whether serum CA 125 levels are correlated with the severity and prognosis of PH remains unclear.…”

Section: Introductionsupporting

confidence: 79%

See 2 more Smart Citations

Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension

Zhang

Jin

Zhao

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Background: Emerging evidence has showed that serum carbohydrate antigen 125 (CA 125) levels are associated with the severity and prognosis of heart failure. However, its role in pulmonary hypertension remains unclear. This study aimed to investigate the clinical, echocardiographic, hemodynamic, and prognostic associations of CA 125 in pulmonary hypertension.Methods and Results: We conducted a retrospective cohort study of all idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients receiving CA 125 measurement in Fuwai Hospital (January 1, 2014–December 31, 2018). The primary end-point was cumulative 1-year clinical worsening-free survival rate. Linear regression was performed to assess the association between CA 125 and clinical, echocardiographic, and hemodynamic parameters. Cox proportional hazards models were used to assess the association between CA 125 and clinical worsening events. Receiver operating characteristic (ROC) curve analysis was performed to determine the predictive performance of CA 125. A total of 231 patients were included. After adjustment, CA 125 still positively correlated with World Health Organization functional class, NT-proBNP, right ventricular end-diastolic diameter, pericardial effusion, mean right atrial pressure and pulmonary arterial wedge pressure; negatively correlated with 6-min walk distance, left ventricular end-diastolic diameter, mixed venous oxygen saturation, and cardiac index. After adjustment, CA 125 > 35 U/ml was associated with over 2 folds increased risk of 1-year clinical worsening. Further, ROC analysis showed that CA 125 provided additional predictive value in addition to the established pulmonary hypertension biomarker NT-proBNP.Conclusion: CA 125 was associated with functional status, echocardiography, hemodynamics and prognosis of pulmonary hypertension.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Ca 125 Is Weakly Associated With Established Markers Of Ph Severitysupporting

confidence: 83%

See 1 more Smart Citation

Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension

Zhang

Jin

Zhao

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…The assay method was based on non-competitive (sandwiched) antibody immunoassay. It was performed according to the manufacture's manual instruction [19].…”

Section: Methodsmentioning

confidence: 99%

Fractional Uric Acid Excretion and C-Reactive Protein Concentration in Type 2 Diabetes Mellitus: The Influence of Glycemic Control

Ekaidem¹,

I.S.²,

ab³

et al. 2020

IJRP

View full text Add to dashboard Cite

This study investigated the influence of glycemic control on fractional uric acid excretion and the concentration of C-reactive protein (CRP) in type 2diabetes mellitus. A total of 120 subjects consisting of 76 confirmed diabetic patients, as cases and 44 apparently healthy volunteers served as control, participated in the study. Venous blood and early morning urine were obtained for estimations of CRP, uric acid and creatinine concentrations. The results showed that serum C-reactive protein concentrations were significantly higher in diabetics than in non-diabetic control (p = 0.000) however, serum uric acid, creatinine and uric acid: creatinine ratio were similar in both groups (p = 0.401, p = 0.248, p = 0.141 respectively). The fractional excretion of uric acid in diabetics was also significantly higher than non-diabetics. Among the diabetics, patients with positive HbA1c (poorly controlled diabetics) had significantly higher concentration of Creactive protein (p = 0.05) and fasting plasma glucose than those with negative HbA1c (better controlled diabetics). However, fractional excretion of uric acid was not significantly different in the HbA1c positive and the negative patients. Pearson bivariate correlation analysis showed that glycated hemoglobin (HbA1c) related positively and significantly with Creactive protein among the diabetics (r = 0.333, p = 0.003) but did not show significant relationship with concentrations of uric acid in serum and urine as well as with fractional excretion of uric acid. Binary logistic regression analysis also showed that a unit increment in the odds of

show abstract

“…The plasma carbohydrate antigen 125 (CA125) demonstrates an increased expression in adult and pediatric patients suffering from heart failure and PH. 8 , 9 The high molecular weight glycoprotein CA125 is synthesized by epithelial serous cells. CA125 presents a complex molecular structure with an intracytoplasmic transmembrane domain and an extracellular domain consisting of oligosaccharide chains.…”

Section: Introductionmentioning

confidence: 99%

CA125: a novel cardiac biomarker for infants with congenital diaphragmatic hernia

et al. 2022

View full text Add to dashboard Cite

Background The carbohydrate antigen 125 (CA125) was proven as a robust biomarker for risk stratification in adults with heart failure. This is the first study analyzing CA125 in a cohort of infants with congenital diaphragmatic hernia (CDH). Methods Sixty-eight infants with CDH, treated at the University Children’s Hospital Bonn (Germany), between January 2018 and February 2021, were prospectively enrolled for analysis. CA125 values were measured at the following timepoints: 6,12, 24, 48 h, and during ECMO daily from day 1 to day 7. Results In infants not surviving to discharge, CA125 values were significantly higher at day 1 (6, 12, and 24 h). Infants with subsequent need for ECMO presented significantly higher CA125 values at 12 h of life. During ECMO, CA125 values measured at day 1 were significantly higher in infants not surviving to discharge. In the ROC analysis, a CA125 value of ≥10 U/ml was calculated as optimal cut-off for the prediction of ECMO and in-hospital mortality. CA125 values correlated significantly with the severity of PH and ventricular dysfunction. Conclusions CA125 values correlate significantly with echocardiographic markers of PH and ventricular dysfunction and correlate significantly with parameters of disease severity (need for ECMO, mortality). Impact CA125 was proven as robust cardiac biomarker in adult cohorts. Information about the utility as a biomarker in neonatal cohorts is lacking. This is the first study analyzing CA125 as a cardiac biomarker in a cohort of infants with congenital diaphragmatic hernia (CDH). CA125 correlates significantly with markers of echocardiographic assessment (PH and ventricular dysfunction) in infants with CDH and helps to identify infants at high risk for ECMO and in-hospital mortality. The results underline the need for the inclusion of cardiac biomarkers in the clinical routine in neonates at risk for cardiopulmonary failure.

show abstract

Biomarker and shear stress in secondary pediatric pulmonary hypertension

Cited by 7 publications

References 27 publications

Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension

Carbohydrate Antigen 125 Is a Biomarker of the Severity and Prognosis of Pulmonary Hypertension

Fractional Uric Acid Excretion and C-Reactive Protein Concentration in Type 2 Diabetes Mellitus: The Influence of Glycemic Control

CA125: a novel cardiac biomarker for infants with congenital diaphragmatic hernia

Contact Info

Product

Resources

About